(Q35551522)

8 August 2017

1 reference

title

HER2-directed therapy: current treatment options for HER2-positive breast cancer (English)

1 reference

8 August 2017

1 reference

Shahid Ahmed

1

1 reference

8 August 2017

Amer Sami

series ordinal

2

1 reference

8 August 2017

Jim Xiang

series ordinal

3

1 reference

8 August 2017

30 January 2015

1 reference

8 August 2017

1 reference

8 August 2017

22

1 reference

8 August 2017

2

1 reference

8 August 2017

101-116

1 reference

https://scigraph.springernature.com/pub.10.1007/s12282-015-0587-x

8 August 2017

0 references

cites work

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

HER2 testing in the UK: further update to recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

The 41st David A. Karnofsky Memorial Award Lecture: Academic research worldwide--quo vadis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Pertuzumab: new hope for patients with HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

HER2 therapy--an abundance of riches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Including persons with HIV infection in cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-015-0587-X

10.1007/S12282-015-0587-X

21 January 2018

Identifiers

DOI

1 reference

release_ykkqypyuzzgebj7xugu5g2rr74

8 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ykkqypyuzzgebj7xugu5g2rr74

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference